Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%

Long‐acting beta2‐agonist plus tiotropium vs tiotropium

Hospital admission (exacerbation) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease

Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (exacerbation) compared with tiotropium alone (low certainty).

1 finding from 1 review

Long‐acting beta₂‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta₂‐agonist alone for… 2015 · Cochrane Headline outcomes only
OR 1.02 [0.8, 1.28]
4 studies · 4856 participants
Low

Long‐acting beta2‐agonist plus tiotropium vs long‐acting beta2‐agonist alone

Hospital admission (exacerbation) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease

Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (exacerbation) compared with long‐acting beta2‐agonist alone (low certainty).

1 finding from 1 review

Long‐acting beta₂‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta₂‐agonist alone for… 2015 · Cochrane Headline outcomes only
OR 0.9 [0.66, 1.22]
3 studies · 3514 participants
Low

Aclidinium bromide vs tiotropium

Hospital admission (exacerbation) · patients with stable chronic obstructive pulmonary disease

It is very uncertain whether aclidinium bromide changes hospital admissions due to exacerbations compared with tiotropium (very low certainty).

1 finding from 1 review

Aclidinium bromide for stable chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
OR 0.54 [0.07, 4.11]
2 studies · 729 participants
Very low